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Effect of Cannabis Use on Human 
Immunodeficiency Virus DNA During 
Suppressive Antiretroviral Therapy
Antoine Chaillon, Masato Nakazawa, Christy Anderson, Aaron Christensen-Quick, 
Ronald J. Ellis, Donald Franklin, Sheldon R. Morris, and Sara Gianella
Division of Infectious Diseases, University of California, San Diego, La Jolla
Cannabis use is frequent among people living with human im-
munodeficiency virus (HIV) and is associated with reduced 
systemic inflammation. We observed a faster HIV DNA decay 
during antiretroviral therapy among cannabis users, compared 
to those with no drug use. No cannabis effect was observed on 
cellular HIV RNA transcription.
Keywords. MSM; cannabis; HIV DNA; cellular 
transcription.
Cannabis is widely consumed in the United States [1], particularly 
among people living with human immunodeficiency virus (HIV) 
[2–4], and this has fostered an important debate regarding the 
impact of cannabis on virologic and inflammatory biomarkers. 
On one hand, a recent study reported reduced adherence to anti-
retroviral therapy (ART) and retention in care in cannabis users 
[5], and 2 other studies found no effects of cannabis on viral sup-
pression [4, 6]. On the other hand, 1 study has demonstrated ben-
eficial impacts of cannabis on plasma HIV RNA among recently 
infected people living with HIV (PLWH) [7]. More recently, 
Manuzak et al [8] evaluated the impact of cannabis use on in-
flammation and immune activation in ART-treated PLWH and 
reported that cannabis use was associated with (1) reduced acti-
vation of CD4+ and CD8+ T cells and (2) a shift in the composi-
tion of the monocyte populations in peripheral blood.
Here, we investigated the effect of cannabis use (with or 
without other drugs) on the decay and transcriptional activity 
of the HIV reservoir during suppressive ART.
METHODS
Ethics Statement
The study was approved by the University of California 
San Diego Human Research Protections Program. All adult 
participants provided written informed consent.
Study Cohort and Clinical Data
There were 48 men who have sex with men (MSM) coenrolled 
in the San Diego Primary Infection Resource Consortium 
[9, 10] and in the Translational Methamphetamine Acquired 
Immunodeficiency Syndrome (AIDS) Research Center cohort 
[11]. The estimated duration of infection (EDI) was determined 
using serologic and virologic parameters [12]. A median of 4 
(interquartile range [IQR] 1–5) longitudinal peripheral blood 
mononuclear cells (PBMCs) and plasma samples per individual 
were collected over a median of 22  months (IQR 12–31) fol-
lowing ART initiation. Absolute CD4+ and CD8+ T cell counts, 
plasma HIV RNA levels (Amplicor, Roche), and self-reported 
ART adherence were measured.
To ascertain substance use (not including alcohol), we 
utilized 3 validated questionnaires, including the World Health 
Organization Composite International Diagnostic Interview–
Substance Abuse Module 2.1 [11, 13, 14]. We were primarily 
interested in the effect of cannabis on cellular HIV DNA and 
HIV RNA. Due to the small sample size and to reduce the false 
discovery rate, we combined all other drugs (except cannabis). 
This yielded 4 groups, based on self-reported drug use: (1) no 
drug use; (2) cannabis use only; (3) use of drugs other than can-
nabis (“other drugs”); and (4) use of both cannabis and other 
drugs (“both drugs”).
Total Cellular Human Immunodeficiency Virus DNA and RNA
DNA was extracted from 5 million PBMCs for each time point 
using an AllPrep DNA/RNA Mini Kit (Qiagen, CA). Total HIV 
DNA (pol) was quantified by droplet digital polymerase chain 
reaction and normalized to the housekeeping gene RPP30 [15]. 
Levels of all fully elongated and correctly processed HIV mRNA 
molecules were quantified [16] and normalized to total RNA 
concentration [17].
Flow Cytometry
Markers of T cell activation (CD38+HLA-DR+) and monocyte 
activation (CD16+) were assessed by flow cytometry [18].
Statistical Analyses
We developed (generalized) linear mixed-effects regression 
models to investigate the relationship of cannabis and other 
drugs on 2 outcomes during ART: (1) changes in HIV DNA 
levels, and (2) cell-associated HIV RNA transcripts (detectable 
or undetectable). For each model, we included a random inter-
cept for subject and the following fixed effects: (1) time from 
ART initiation (ie, slope); (2) drug use; and (3) time by drug use 
(ie, the difference in slopes). To determine which fixed effects 
to include in the final model, we tested whether the outcome 
changed over time among all participants. If it did change at 
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the 10% significance level, we subsequently tested whether 
the drug user groups differed in the rate of change and in the 
outcome level at ART initiation; if not, we tested whether the 
groups differed in the overall outcome level. To control for 
other sources of variability, we added relevant covariates (ie, 
age, time from EDI to ART, CD4 count, CD4/CD8 ratio, mean 
% activated [CD38+HLA-DR+] of CD4+ and CD8+ T cells, and 
mean % of CD14+CD16+ monocytes), if associated with the out-
come at P < .10 in individual models. Our final models include 
all predictors and covariates that were significant at P  <  .05. 
Because 34% of all time points exhibited levels of cellular HIV 
RNA below the limits of detection, we used mixed-effects lo-
gistic regression to analyze this outcome. Data are expressed as 
median (IQR).
RESULTS
Study Cohort and Samples
This study evaluated 206 blood samples from 48 MSM who 
initiated ART within a median of 4  months (IQR 1–6) from 
EDI and achieved suppressed HIV RNA within a median of 
5  months (IQR 3–8), without any documented blips of HIV 
RNA replication. Of the 48 individuals, 10 (21%) reported 
no drug use, 5 (11%) reported use of cannabis only, 16 (33%) 
reported use of drugs other than cannabis, and 17 (35%) re-
ported use of cannabis and other drugs. Summaries of cohort 
characteristics and drug self-reports at ART initiation are pro-
vided in Supplementary Tables 1 and 2.
Predictors of Human Immunodeficiency Virus DNA Levels and Decay
The median unadjusted HIV DNA level at ART initiation was 
2.4 log10 copies/10
6 cells (IQR 1.0–3.1) with a significant de-
crease of HIV DNA over time among all participants (P < .01; 
Supplementary Table 3). Cannabis-only users had signifi-
cantly greater HIV DNA levels at the time of ART initiation 
(P = .04), but subsequently experienced a faster HIV DNA decay, 
compared to participants with no drug use (P = .04; Figure 1). 
Participants who used other drugs (with or without cannabis) 
had similar levels of HIV DNA at ART initiation (P =  .41 and 
P = .66, respectively) and during ART (P = .43 and P = .76, re-
spectively), compared to those who used no drugs. The 4 groups 
did not differ in baseline CD4 counts (P = .80) or EDIs (P = .46).
Regarding markers of cellular activation, study participants 
taking other drugs had a persistent, higher proportion of ac-
tivated (CD38+HLA-DR+) CD8+ T cells, as compared to 
those who used no drugs, even after controlling for signifi-
cant covariates. There were no differences by groups related 
to CD38+HLA-DR+CD4+ T cells or CD14+CD16+ monocytes. 
Overall, the mean percentage of CD38+HLA-DR+CD8+ T cells 
was positively associated with HIV DNA levels in the individual 
model (P < .02), but this was no longer significant when drug 
groups were included (P = .08).
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Figure 1. Observed HIV DNA (log10 copies/10
6 CD4+) in cohort during ART as a function of time (Ln months since ART Initiation) and drug use. The thin lines and dots 
indicate individual data points. Thick lines and shaded areas indicate model-estimated values and their 95% confidence intervals. *P < .05: the mean HIV DNA level at ART 
initiation and slope differences compared to the no-drug group. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus. 
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Cellular Human Immunodeficiency Virus RNA Transcription
The median levels of cellular HIV RNA at baseline were 4.9 log10 
copies/ml (IQR 3.8–5.7; Supplementary Table 1), and all of the 
participants had detectable levels at ART initiation. Participants 
who reported use of cannabis (with or without other drugs), 
did not exhibit significantly different proportions of detectable 
cellular HIV RNA (P = .59 and P = .28, respectively). However, 
participants who used other drugs were significantly more 
likely to have detectable cellular HIV RNA levels during ART 
(P  =  .01). Similarly, participants with higher peak HIV RNA 
levels (before ART initiation) and higher mean percentages of 
activated CD8+ T cells had more detectable cellular HIV RNA 
levels during ART (P < .05). Participants with higher CD4/CD8 
ratios had less detectable cellular HIV RNA levels (P  <  .10). 
Interestingly, only the other drug effect remained significant for 
cellular HIV RNA when included in a final multivariate model 
(P = .01; other effects, P > .4; Supplementary Table 4).
DISCUSSION
In this longitudinal study of PLWH with well-characterized 
histories of substance use, we found that exclusive use of cannabis 
was associated with a faster decay of HIV DNA, but had no im-
pact on cell-associated HIV RNA transcription or cellular activa-
tion during suppressive ART. However, the consumption of other 
drugs was associated with increased CD8+ T cell activation and 
with increased cellular HIV RNA transcription during ART. Our 
results are consistent with a previous study reporting that cannabis 
use was associated with lower plasma HIV RNA levels among re-
cently infected PLWH [7], and with reports of reduced HIV repli-
cation and cellular infection rates in the presence of cannabinoids 
in vitro [19, 20]. Further, cannabis use has been associated with 
decreased frequencies of interleukin 23 and tumor necrosis factor 
α [8] and, more recently, with the reduction of interferon-γ in-
ducible protein 10 levels in plasma [21]. Altogether, these findings 
point to a potential anti-inflammatory effect of cannabis that, in 
turn, might positively impact HIV replication and persistence 
[22], although another study has suggested that tetrahydrocan-
nabinol may enhance HIV replication by suppressing immune 
functions in mice [23], and this possibility should be evaluated in 
future, larger clinical studies. In our study, the effect of cannabis 
on HIV DNA was not evident when cannabis was used in com-
bination with any other drugs, highlighting the complex interplay 
between drug use and viral infections.
The small sample size and the multiple potential confounding 
factors among participants with a complex history of drug use 
are major limitations to this report. Furthermore, cannabis 
use was not confirmed by the direct measurement of cannabis 
metabolites, and only relied on self-report. While inaccurate 
self-reporting could confound our observations, studies have 
demonstrated the reliability of self-reported drug use [24].
The mechanisms by which cannabis impacts the HIV res-
ervoir—whether directly or indirectly by limiting immune 
activation, the infection of CD4+ T cells, and macrophages and 
inflammation—remain uncertain. Further work is necessary 
to explore these mechanisms and the interactions with other 
drugs, which have been associated with contradictory effects on 
the immune system. These findings may have implications for 
and reaffirm the need for regular screening for substance use 
in HIV care settings and for a holistic approach to HIV cures 
from healthcare providers, physicians, epidemiologists, and 
researchers.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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